Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1341 in Parkinson's Disease
NCT04449484Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing MEDI1341 with Placebo (2 arms). Primary endpoints: Adverse Events at 28 weeks, Vital Signs at 21 weeks and 8 more. Started Aug 2020; status: completed.
02
Drugs
MEDI1341
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04449484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449484.